Tuesday, March 5, 2019
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Abbott (ABT) and PayPal (PYPL). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Strong Buy-ranked Boeing 's shares have gained +34.2% year to date, outperforming the S&P 500, which increased +11.4% during the same time period. The company's 20-year market outlook forecasts commercial jetliner demand to increase by 4.1%, with single-aisle jets being the major driver behind this demand growth.
Boeing expects the commercial fleet to be fueled by sustained annual growth in commercial passenger traffic along with a big wave of retiring, old planes. The Zacks analyst thinks Boeing's strong balance sheet and cash flows provide financial flexibility in matters of incremental dividend, ongoing share repurchases and earnings accretive acquisitions.
Its revenue exposure is also spread across more than 90 countries around the globe. However, this aerospace giant may face competitive challenges once new manufacturers like China enters the commercial jet space.
(You can read the full research report on Boeing here >>> ).
Shares of Abbott have gained +9.9% over the past three months, outperforming the S&P 500, which has increased +3.6% over the same period. Abbott exited the fourth quarter on a mixed note with earnings in line with expectations and revenues missing the mark. Increasing currency headwinds to some extent dented the company's international performance.
Meanwhile, emerging market performance has been promising. The Zacks analyst is optimistic about the strong and consistent performance by the company's EPD and Medical Devices segments organically. The company has been hogging the limelight within Diabetic Care on growth with FreeStyle Libre. Within Structural Heart, worldwide strong uptake of MitraClip improves further following the FDA approval of its upgraded version.
This apart, synergies from Alere consolidation in the form of revenues from Rapid Diagnostics have been driving growth. On the flip side, sluggish Vascular arm in the United States continues to dent growth.
(You can read the full research report on Abbott here >>> ).
PayPal 's shares have outperformed the S&P 500 in the past year (+22.1% vs. +2.6%). The Zacks analyst thinks PayPal's rising transaction revenues, growth in active customer accounts and benefits from acquisitions of Hyperwallet and iZettle remain growth drivers. Further, Venmo's improving monetization efforts, partnerships and its increasing adoption rate across various platforms are aiding the company's user base.
Strong momentum of PayPal in international markets, especially in India and Japan remained a major positive. However, adverse foreign exchange translations, competition from Square and interest rate risks are concerns. Further, sale of the credit portfolio to Synchrony is expected to continue impacting negatively. Also, a challenging macroeconomic environment in China and the UK remain concerns.
(You can read the full research report on PayPal here >>> ).
Other noteworthy reports we are featuring today include Bristol-Myers (BMY), Caterpillar (CAT) and Anthem (ANTM).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Per the Zacks analyst, acquisitions and active collaborations have helped Anthem expand its portfolio and boost its Medicare Advantage business.
Per the Zacks analyst, Ventas' efforts to fortify its portfolio on the back of higher investments in life-science real estate look good.
Per the Zacks analyst, Yandex is riding on its strong position in the Russian search market owing to its rising desktop and mobile search shares.
Per the Zacks analyst, Goldcorp's focus on reducing mining costs and improving productivity should boost its margins amid declining gold production.
The Zacks analyst appreciates the growth in passenger revenues on the back of strong demand for air travel.
Per the Zacks analyst ONE Gas' $2B capital outlay for 2019 to 2023 time frame will strengthen its operations.
Per the Zacks analyst, growing demand for glass packaging, focus on productivity improvement and costs reductions will drive growth for Owens-Illinois.
Per the Zacks analyst, Bristol-Myers' Opdivo's performance is being boosted by the uptake in new indications.
Cardinal Health rides on solid prospects of its Pharmaceutical unit. The Zacks analyst is also optimistic about the company's strength in the Specialty business.
Per the Zacks analyst, loan growth, higher interest rates and solid asset quality will support Zions. Also, removal of SIFI label allows flexibility in announcing steady capital deployment actions.
Per the Zacks analyst, the recent slowdown in demand in China markets along with material costs inflation and supply chain challenges will dent Caterpillar's results.
Per the Zacks analyst, input cost inflation, higher transportation expenses and increased start-up costs have been impacting Mohawk's bottom line.
Coty's Consumer Beauty unit has long been pressurized by supply chain woes, softness in mass beauty categories and competition. Per the Zacks analyst, recovery at this unit is likely to take time.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.